The historical rank and industry rank for Jacobio Pharmaceuticals Group Co's EV-to-FCF or its related term are showing as below:
JBPHF'
s EV-to-FCF Range Over the Past 10 Years
Min: -84.19 Med: -6.92 Max: 91.28
Current: -9.69
During the past 8 years, the highest EV-to-FCF of Jacobio Pharmaceuticals Group Co was 91.28. The lowest was -84.19. And the median was -6.92.
JBPHF's EV-to-FCF is ranked worse than 100% of 333
companies
in the Biotechnology industry
Industry Median: 14.65
vs JBPHF: -9.69
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jacobio Pharmaceuticals Group Co (OTCPK:JBPHF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jacobio Pharmaceuticals Group Co's PE Ratio (TTM) for today is calculated as:
Jacobio Pharmaceuticals Group Co's share price for today is $0.8677.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jacobio Pharmaceuticals Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.027.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Jacobio Pharmaceuticals Group Co EV-to-FCF Related Terms
Jacobio Pharmaceuticals Group Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobio Pharmaceuticals Group Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Jacobio Pharmaceuticals Group Co's EV-to-FCF falls into.
Jacobio Pharmaceuticals Group Co's current Enterprise Value is $288.27 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jacobio Pharmaceuticals Group Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-29.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co (JBPHF) has a EV-to-FCF of -9.67 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. According to the industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #999999 out of 333 companies in the Biotechnology industry.
Is Jacobio Pharmaceuticals Group Co's EV-to-FCF too high?
Jacobio Pharmaceuticals Group Co's current EV-to-FCF is -9.67. Based on the distribution chart, Jacobio Pharmaceuticals Group Co ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #999999 out of 333 companies for EV-to-FCF. This places Jacobio Pharmaceuticals Group Co in the lower half of its industry. The industry median EV-to-FCF is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobio Pharmaceuticals Group Co's current EV-to-FCF is -9.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current EV-to-FCF of -9.67. The stock's GF Value™ is $0.42, compared to a current price of $0.87 — trading 106.6% above its estimated fair value. The current EV-to-FCF is -9.67. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current EV-to-FCF is -9.67 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued.
The current stock price of $0.87 is trading 106.6% above its estimated GF Value™ of $0.42.
Key valuation signals for JBPHF:
EV-to-FCF: -9.67
GF Value™: $0.42 vs. price of $0.87 (106.6% above fair value)
No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobio Pharmaceuticals Group Co Business Description
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score
Get the complete analysis for JBPHF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JBPHF has been successfully added to your 
